Methotrexat Accord (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form needed for DNA, RNA and protein synthesis. This inhibition limits the proliferation of rapidly dividing cells and also raises adenosine levels, providing anti‑inflammatory effects that help reduce disease activity.

The dose of Methotrexat Accord is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment goals. Dosage regimens can differ markedly between rheumatologic and oncologic uses, so the prescriber sets the appropriate schedule.

Methotrexat Accord is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal malformations and loss. It is also not recommended while breastfeeding, as methotrexate can be excreted in breast milk and may harm the infant.

To request Methotrexat Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that can be taken orally and is generally less expensive. It has a well‑characterised safety profile but requires regular laboratory monitoring. Biologics target specific cytokines and may have fewer systemic toxicities, yet they are administered by injection and often carry higher acquisition costs.

Methotrexat Accord should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure the packaging remains tightly closed until use.

Methotrexat Accord is taken orally with a full glass of water. Depending on the prescribing regimen, it may be taken with or without food. Patients should follow the prescriber’s instructions regarding timing, whether a single weekly dose or divided doses, and any accompanying folic‑acid supplementation.

The most serious adverse events include bone‑marrow suppression (leading to anemia, neutropenia or thrombocytopenia), severe hepatic injury such as fibrosis or cirrhosis, and pulmonary toxicity presenting as interstitial pneumonitis. Early recognition of symptoms—such as persistent fatigue, jaundice, shortness of breath or unexplained bruising—is essential for prompt medical evaluation.

Methotrexat Accord is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, and patients with known hypersensitivity to methotrexate or any of its excipients. It should also be avoided in patients with active infections or uncontrolled immune‑mediated diseases unless closely monitored by a specialist.